Press release
Provecs Medical Announces Publication of Scientific Review of Gene Therapy in Oncology
-- Peer-reviewed paper in Human Gene Therapy provides comprehensive overview of using gene therapy to address multiple targets --Hamburg (December 14, 2017) - Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the publication of a review highlighting the use of gene therapy approaches in immuno-oncology to address multiple targets with a single drug. The paper entitled “Immuno-Oncology - the Translational Runway for Gene Therapy” will appear in the December issue of Human Gene Therapy, a peer-reviewed publication covering all aspects of human gene therapy. The review is already available online at http://online.liebertpub.com/doi/pdfplus/10.1089/hum.2017.145.
“It is known today that a successful strategy against cancer needs to address multiple targets or pathways of the immune system in parallel to ensure that it recognizes and eliminates tumor cells,” said Dr. Frank Schnieders, CEO of Provecs Medical. “In past decades, gene therapy research has developed a vast array of technologies not only to transfect all sorts of cells and tissues, ex vivo as well as in vivo, but also to organize, regulate and stabilize the genetic content of the vectors. Gene therapy therefore is the best available toolbox for the targeted delivery of several therapeutic entities to the tumor and its microenvironment. It was our goal to summarize the impact of gene therapy on novel approaches in cancer therapy that may well lead to breakthrough treatments against tumors.”
Provecs is a pioneer in the tumor gene therapy field and has developed ENVIRO, a unique, patented adenoviral platform for the targeted delivery of up to four biologicals combined in one product. The first product candidate, Immunalon®, is expressing three potent immune-modifying signaling proteins - Interleukin-12, Interleukin-2 and CD137 ligand - to turn off tumor-mediated immune suppression and to promote T- cell infiltration of tumors and recognition of cancer cells. These molecules stimulate the activation, proliferation and survival of a synergizing network of tumor-defensive immune cells in both the innate and the adaptive immune system. At present, Immunalon® is being developed for the treatment of a wide range of solid cancers. In urinary bladder cancer, it is partnered with Medac Gesellschaft für klinische Spezialpräparate mbH (Wedel, Germany).
###
Contact:
Company inquiries:
Dr. Frank Schnieders, CEO
Tel. +49 (0)40 4 12 63 26 83
schnieders(at)provecs.com
Media Inquiries:
akampion
Dr. Ludger Wess or Ines-Regina Buth
Tel.: +49 (0)40 88 16 59 64 / +49 (0)30 2363 2768
info(at)akampion.com
About Provecs Medical GmbH
Provecs Medical is a private biopharmaceutical company, based in Hamburg (Germany) and specialized in immune-oncology. Based on its multivalent adenoviral ENVIRO technology platform, the company has developed unique solutions to re-program the immunologic barriers in the tumor microenvironment. Provecs has established a comprehensive proof-of-concept platform, named EXVIRO, for ex-vivo therapy simulation in primary human cancer tissues. Immune processes are monitored by big data transcriptome profiling, bioinformatics, and tissue immune imaging technologies. Provecs´ lead product Immunalon® is being developed for the treatment of solid cancers with a focus on urinary bladder cancer. www.provecs.com
Contact:
Provecs Medical
Dr. Frank Schnieders, CEO
Martinistr. 64
20251 Hamburg
Germany
Tel. +49 (0)40 4 12 63 26 83
schnieders(at)provecs.com
Media Inquiries:
akampion
Dr. Ludger Wess or Ines-Regina Buth
Tel.: +49 (0)40 88 16 59 64 / +49 (0)30 2363 2768
info(at)akampion.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Provecs Medical Announces Publication of Scientific Review of Gene Therapy in Oncology here
News-ID: 860248 • Views: …
More Releases from Provecs Medical
Provecs Medical closes immuno-oncology collaboration with Medac
- Joint development of Immunalon® in urinary bladder cancer
Hamburg (16 03 2017) - Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the closing of a partnership with oncology pharma company Medac Gesellschaft für klinische Spezialpräparate mbH. The partners aim to develop, manufacture and market Provec’s cancer immunotherapy lead product Immunalon® for the treatment of urinary bladder cancer. Immunalon® is being developed…
More Releases for Gene
DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"
The DNA and Gene Cloning Services Market Size is valued…
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period?
The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88…
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by…
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with…
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,…
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.
In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal…
